164 related articles for article (PubMed ID: 34511320)
1. Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).
Abrisqueta P; Loscertales J; Terol MJ; Ramírez Payer Á; Ortiz M; Pérez I; Cuellar-García C; Fernández de la Mata M; Rodríguez A; Lario A; Delgado J; Godoy A; Arguiñano Pérez JM; Berruezo MJ; Oliveira A; Hernández-Rivas JÁ; García Malo MD; Medina Á; García Martin P; Osorio S; Baltasar P; Fernández-Zarzoso M; Marco F; Vidal Manceñido MJ; Smucler Simonovich A; López Rubio M; Jarque I; Suarez A; Fernández Álvarez R; Lancharro Anchel A; Ríos E; Losada Castillo MDC; Pérez Persona E; García Muñoz R; Ramos R; Yáñez L; Bello JL; Loriente C; Acha D; Villanueva M
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e985-e999. PubMed ID: 34511320
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.
Burger JA; Barr PM; Robak T; Owen C; Ghia P; Tedeschi A; Bairey O; Hillmen P; Coutre SE; Devereux S; Grosicki S; McCarthy H; Simpson D; Offner F; Moreno C; Dai S; Lal I; Dean JP; Kipps TJ
Leukemia; 2020 Mar; 34(3):787-798. PubMed ID: 31628428
[TBL] [Abstract][Full Text] [Related]
3. Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.
Jain N; Croner LJ; Allan JN; Siddiqi T; Tedeschi A; Badoux XC; Eckert K; Cheung LWK; Mukherjee A; Dean JP; Szafer-Glusman E; Seymour JF
Clin Cancer Res; 2024 Feb; 30(3):498-505. PubMed ID: 37955424
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Burger JA; Tedeschi A; Barr PM; Robak T; Owen C; Ghia P; Bairey O; Hillmen P; Bartlett NL; Li J; Simpson D; Grosicki S; Devereux S; McCarthy H; Coutre S; Quach H; Gaidano G; Maslyak Z; Stevens DA; Janssens A; Offner F; Mayer J; O'Dwyer M; Hellmann A; Schuh A; Siddiqi T; Polliack A; Tam CS; Suri D; Cheng M; Clow F; Styles L; James DF; Kipps TJ;
N Engl J Med; 2015 Dec; 373(25):2425-37. PubMed ID: 26639149
[TBL] [Abstract][Full Text] [Related]
5. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.
Woyach JA; Perez Burbano G; Ruppert AS; Miller C; Heerema NA; Zhao W; Wall A; Ding W; Bartlett NL; Brander DM; Barr PM; Rogers KA; Parikh SA; Stephens DM; Brown JR; Lozanski G; Blachly J; Nattam S; Larson RA; Erba H; Litzow M; Luger S; Owen C; Kuzma C; Abramson JS; Little RF; Dinner S; Stone RM; Uy G; Stock W; Mandrekar SJ; Byrd JC
Blood; 2024 Apr; 143(16):1616-1627. PubMed ID: 38215395
[TBL] [Abstract][Full Text] [Related]
6. Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib.
Jacobs R; Lu X; Emond B; Morrison L; Kinkead F; Lefebvre P; Lafeuille MH; Khan W; Wu LH; Qureshi ZP; Levy MY
Future Oncol; 2024 Jan; 20(1):39-53. PubMed ID: 37476983
[TBL] [Abstract][Full Text] [Related]
7. Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia.
Allan JN; Flinn IW; Siddiqi T; Ghia P; Tam CS; Kipps TJ; Barr PM; Elinder Camburn A; Tedeschi A; Badoux XC; Jacobs R; Kuss BJ; Trentin L; Zhou C; Szoke A; Abbazio C; Wierda WG
Clin Cancer Res; 2023 Jul; 29(14):2593-2601. PubMed ID: 37282671
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort.
Martino EA; Mauro FR; Reda G; Laurenti L; Visentin A; Frustaci A; Vigna E; Pepe S; Catania G; Loseto G; Murru R; Chiarenza A; Sportoletti P; Del Principe MI; Laureana R; Coscia M; Galimberti S; Ferretti E; Zucchetto A; Bomben R; Polesel J; Tedeschi A; Rossi D; Trentin L; Neri A; Morabito F; Gattei V; Gentile M
Hematol Oncol; 2024 Jan; 42(1):e3249. PubMed ID: 38287529
[TBL] [Abstract][Full Text] [Related]
9. The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice.
Parikh SA; Achenbach SJ; Call TG; Rabe KG; Ding W; Leis JF; Kenderian SS; Chanan-Khan AA; Koehler AB; Schwager SM; Muchtar E; Fonder AL; McCullough KB; Nedved AN; Smith MD; Slager SL; Kay NE; Finnes HD; Shanafelt TD
Cancer Med; 2020 May; 9(10):3390-3399. PubMed ID: 32187452
[TBL] [Abstract][Full Text] [Related]
10. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Tam CS; Allan JN; Siddiqi T; Kipps TJ; Jacobs R; Opat S; Barr PM; Tedeschi A; Trentin L; Bannerji R; Jackson S; Kuss BJ; Moreno C; Szafer-Glusman E; Russell K; Zhou C; Ninomoto J; Dean JP; Wierda WG; Ghia P
Blood; 2022 Jun; 139(22):3278-3289. PubMed ID: 35196370
[TBL] [Abstract][Full Text] [Related]
11. Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Huber H; Tausch E; Schneider C; Edenhofer S; von Tresckow J; Robrecht S; Giza A; Zhang C; Fürstenau M; Dreger P; Ritgen M; Illmer T; Illert AL; Dürig J; Böttcher S; Niemann CU; Kneba M; Al-Sawaf O; Kreuzer KA; Fink AM; Fischer K; Döhner H; Hallek M; Eichhorst B; Stilgenbauer S
Blood; 2023 Sep; 142(11):961-972. PubMed ID: 37363867
[TBL] [Abstract][Full Text] [Related]
12. Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk.
Stühlinger MC; Weltermann A; Staber P; Heintel D; Nösslinger T; Steurer M
Wien Klin Wochenschr; 2020 Feb; 132(3-4):97-109. PubMed ID: 31414181
[TBL] [Abstract][Full Text] [Related]
13. Incidence of invasive fungal infections in patients with chronic lymphocytic leukemia receiving ibrutinib within the veteran's healthcare administration.
Walker C; Horowitz A; Nooruddin Z; Frei CR
J Oncol Pharm Pract; 2024 Jun; 30(4):673-677. PubMed ID: 37309168
[TBL] [Abstract][Full Text] [Related]
14. A CAPTIVATEing Analysis for Higher-Risk CLL.
Rogers KA
Clin Cancer Res; 2023 Jul; 29(14):2561-2562. PubMed ID: 37289004
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p.
Barnes JI; Divi V; Begaye A; Wong R; Coutre S; Owens DK; Goldhaber-Fiebert JD
Blood Adv; 2018 Aug; 2(15):1946-1956. PubMed ID: 30097461
[TBL] [Abstract][Full Text] [Related]
16. Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study.
Mauro FR; Scalzulli PR; Scarfò L; Minoia C; Murru R; Sportoletti P; Frigeri F; Albano F; Di Renzo N; Sanna A; Laurenti L; Massaia M; Cassin R; Coscia M; Patti C; Pennese E; Tafuri A; Chiarenza A; Galieni P; Perbellini O; Selleri C; Califano C; Ferrara F; Cuneo A; Murineddu M; Palumbo G; Scortechini I; Tedeschi A; Trentin L; Varettoni M; Pane F; Liberati AM; Merli F; Morello L; Musuraca G; Tani M; Ibatici A; Regazzoni G; Di Candia M; Palma M; Arienti D; Molica S
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539561
[TBL] [Abstract][Full Text] [Related]
17. Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Kang DW; Wang L; Short NJ; Ferrajoli A; Wang Y; Zhou S; Shen C
Pharmacoeconomics; 2024 Apr; 42(4):409-418. PubMed ID: 38184494
[TBL] [Abstract][Full Text] [Related]
18. Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study.
Gerhardt A; Dörfel S; Schulz H; Schlag R; Vornholz L; Nejad-Asgari S; Welslau M
Eur J Haematol; 2024 Jun; 112(6):927-937. PubMed ID: 38342972
[TBL] [Abstract][Full Text] [Related]
19. Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion.
Tam CS; Robak T; Ghia P; Kahl BS; Walker P; Janowski W; Simpson D; Shadman M; Ganly PS; Laurenti L; Opat S; Tani M; Ciepluch H; Verner E; Šimkovič M; Österborg A; Trněný M; Tedeschi A; Paik JC; Kuwahara SB; Feng S; Ramakrishnan V; Cohen A; Huang J; Hillmen P; Brown JR
Haematologica; 2021 Sep; 106(9):2354-2363. PubMed ID: 33054121
[TBL] [Abstract][Full Text] [Related]
20. An Anecdotal Case Report of Chronic Lymphatic Leukemia with del(11q) Treated with Ibrutinib: Artificial Nourishment and Physical Activity Program.
Sica A; Sagnelli C; Papa A; Ciccozzi M; Sagnelli E; Calogero A; Martinelli E; Casale B
Int J Environ Res Public Health; 2020 Mar; 17(6):. PubMed ID: 32188040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
